AngioDynamics, Inc.（ANGO）财务数据ANGOAngioDynamics, Inc.

AngioDynamics, Inc. (ANGO) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Med Device, accounting for 51.8% of total sales, equivalent to $44.85M. Another important revenue stream is Med Tech. Understanding this composition is critical for investors evaluating how ANGO navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, AngioDynamics, Inc. maintains a gross margin of 56.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -6.33%, while the net margin is -8.77%. These profitability ratios, combined with a Return on Equity (ROE) of -19.21%, provide a clear picture of how effectively ANGO converts its operational activities into shareholder value.

In the context of the broader market, ANGO competes directly with industry leaders such as DCTH and SGHT. With a market capitalization of $596.75M, it holds a leading position in the sector. When comparing efficiency, ANGO's gross margin of 56.00% stands against DCTH's 89.75% and SGHT's 90.96%. Such benchmarking helps identify whether AngioDynamics, Inc. is trading at a premium or discount relative to its financial performance.

AngioDynamics has shown declining financial performance with a net loss of $11.4 million in Q4 2026 and a gross margin of 50.87%. Total revenue for Q4 2026 was $86.6 million, but year-over-year growth is weak, only 6.9%.